Risultati preclinici e clinici con Gefitinib (ZD1839, Iressa) inibitore del recettore per il fattore di crescita epidermoidale

Translated title of the contribution: Preclinical and clinical results with the epidermal growth factor receptor inhibitor Gefitinib (ZD1839, Iressa)

S. Di Cosimo, G. Ferretti, M. Milella, E. Martinelli, A. Alimonti, P. Papaldo, P. Carlini, A. Fabi, P. Matar, F. Cognetti

Research output: Contribution to journalArticle

Abstract

Since epidermal growth factor receptor (EGFR) is involved in tumor proliferation and angiogenesis, and in the mechanisms of resistance to chemo- and hormono-therapy, it represents a unique promising target for anticancer treatment. Gefinitib (Iressa, ZD1839), an inhibitor of the EGFR tyrosine kinase activity able to bind the intracellular domain of the receptor, is at present in clinical development. In preclinical models Gefitinib induced a dose-dependent response rate in tumor xenografts obtained from different human cancer cells lines. The expression of EGFR in the prior tumor did not appear to be a predictive marker for Gefitinib sensitivity. Furthermore, long-term drug use was well tolerated in mice without inducing resistance. However, tumors started to grow again after treatment interruption. Laboratory findings and in vivo data have prompted the evaluation of Gefitinib administered as a single oral daily dose alone or in combination with conventional anticancer treatment.

Original languageItalian
Pages (from-to)233-241
Number of pages9
JournalMinerva Medica
Volume95
Issue number3
Publication statusPublished - Jun 2004

Fingerprint

Epidermal Growth Factor Receptor
Neoplasms
Heterografts
Protein-Tyrosine Kinases
gefitinib
Cell Line
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Risultati preclinici e clinici con Gefitinib (ZD1839, Iressa) inibitore del recettore per il fattore di crescita epidermoidale. / Di Cosimo, S.; Ferretti, G.; Milella, M.; Martinelli, E.; Alimonti, A.; Papaldo, P.; Carlini, P.; Fabi, A.; Matar, P.; Cognetti, F.

In: Minerva Medica, Vol. 95, No. 3, 06.2004, p. 233-241.

Research output: Contribution to journalArticle

Di Cosimo, S. ; Ferretti, G. ; Milella, M. ; Martinelli, E. ; Alimonti, A. ; Papaldo, P. ; Carlini, P. ; Fabi, A. ; Matar, P. ; Cognetti, F. / Risultati preclinici e clinici con Gefitinib (ZD1839, Iressa) inibitore del recettore per il fattore di crescita epidermoidale. In: Minerva Medica. 2004 ; Vol. 95, No. 3. pp. 233-241.
@article{df197a208dd7428bb027a86a51105079,
title = "Risultati preclinici e clinici con Gefitinib (ZD1839, Iressa) inibitore del recettore per il fattore di crescita epidermoidale",
abstract = "Since epidermal growth factor receptor (EGFR) is involved in tumor proliferation and angiogenesis, and in the mechanisms of resistance to chemo- and hormono-therapy, it represents a unique promising target for anticancer treatment. Gefinitib (Iressa, ZD1839), an inhibitor of the EGFR tyrosine kinase activity able to bind the intracellular domain of the receptor, is at present in clinical development. In preclinical models Gefitinib induced a dose-dependent response rate in tumor xenografts obtained from different human cancer cells lines. The expression of EGFR in the prior tumor did not appear to be a predictive marker for Gefitinib sensitivity. Furthermore, long-term drug use was well tolerated in mice without inducing resistance. However, tumors started to grow again after treatment interruption. Laboratory findings and in vivo data have prompted the evaluation of Gefitinib administered as a single oral daily dose alone or in combination with conventional anticancer treatment.",
keywords = "Growth factors, Medical oncology, Neoplasms, Therapy",
author = "{Di Cosimo}, S. and G. Ferretti and M. Milella and E. Martinelli and A. Alimonti and P. Papaldo and P. Carlini and A. Fabi and P. Matar and F. Cognetti",
year = "2004",
month = "6",
language = "Italian",
volume = "95",
pages = "233--241",
journal = "Minerva Medicolegale e Archivio di Antropologia Criminale",
issn = "0026-4806",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "3",

}

TY - JOUR

T1 - Risultati preclinici e clinici con Gefitinib (ZD1839, Iressa) inibitore del recettore per il fattore di crescita epidermoidale

AU - Di Cosimo, S.

AU - Ferretti, G.

AU - Milella, M.

AU - Martinelli, E.

AU - Alimonti, A.

AU - Papaldo, P.

AU - Carlini, P.

AU - Fabi, A.

AU - Matar, P.

AU - Cognetti, F.

PY - 2004/6

Y1 - 2004/6

N2 - Since epidermal growth factor receptor (EGFR) is involved in tumor proliferation and angiogenesis, and in the mechanisms of resistance to chemo- and hormono-therapy, it represents a unique promising target for anticancer treatment. Gefinitib (Iressa, ZD1839), an inhibitor of the EGFR tyrosine kinase activity able to bind the intracellular domain of the receptor, is at present in clinical development. In preclinical models Gefitinib induced a dose-dependent response rate in tumor xenografts obtained from different human cancer cells lines. The expression of EGFR in the prior tumor did not appear to be a predictive marker for Gefitinib sensitivity. Furthermore, long-term drug use was well tolerated in mice without inducing resistance. However, tumors started to grow again after treatment interruption. Laboratory findings and in vivo data have prompted the evaluation of Gefitinib administered as a single oral daily dose alone or in combination with conventional anticancer treatment.

AB - Since epidermal growth factor receptor (EGFR) is involved in tumor proliferation and angiogenesis, and in the mechanisms of resistance to chemo- and hormono-therapy, it represents a unique promising target for anticancer treatment. Gefinitib (Iressa, ZD1839), an inhibitor of the EGFR tyrosine kinase activity able to bind the intracellular domain of the receptor, is at present in clinical development. In preclinical models Gefitinib induced a dose-dependent response rate in tumor xenografts obtained from different human cancer cells lines. The expression of EGFR in the prior tumor did not appear to be a predictive marker for Gefitinib sensitivity. Furthermore, long-term drug use was well tolerated in mice without inducing resistance. However, tumors started to grow again after treatment interruption. Laboratory findings and in vivo data have prompted the evaluation of Gefitinib administered as a single oral daily dose alone or in combination with conventional anticancer treatment.

KW - Growth factors

KW - Medical oncology

KW - Neoplasms, Therapy

UR - http://www.scopus.com/inward/record.url?scp=4744348435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4744348435&partnerID=8YFLogxK

M3 - Articolo

C2 - 15289751

AN - SCOPUS:4744348435

VL - 95

SP - 233

EP - 241

JO - Minerva Medicolegale e Archivio di Antropologia Criminale

JF - Minerva Medicolegale e Archivio di Antropologia Criminale

SN - 0026-4806

IS - 3

ER -